ALFA Finder| Management target | Revenue FY30 |
|---|
| Revenue growth | 13% YoY |
|---|---|
| Margins | Adjusted EBITDA margins improved to 19.4% from 18.2% YoY |
| Demand visibility | Strong; 550+ new patient registrations at North Bengaluru facility |
| Management confidence | High regarding oncology focus and market leadership |
Growth
Revenue grew 13% YoY to INR 6,951 Mn; PAT surged 190% YoY to INR 138 Mn.
Outlook
Targeting 1,000 bed addition by FY30 via 60% brownfield expansion and ~INR 5,500 Mn total capex.
Risks
Near-term margins impacted by North Bangalore startup losses (INR 70 Mn) and EPCG provisions.
Last quarter's promises, checked
Delivered
- Guided 15%+ revenue growth → delivered 13% (ex-fertility 13.4%) (= BEAT)
- Guided 20% EBITDA growth → delivered 20% (= BEAT)
- Launch North Bangalore by Q4 FY26 → operationalized May 2026 (= BEAT)
Partly delivered
- Guided 18.5% YTD EBITDA margin → delivered 19.4% in Q1 FY27 (= BEAT)
- Guided 5% ARPP growth → delivered 2% in current quarter (= MISS)
Investor Presentation filed with BSE, NSE: HCG. Summary written with AI assistance from the document.
Healthcare Global Enterprises Ltd: key numbers
- Share price
- ₹568.85
- Market cap
- ₹8,493 Cr
- Revenue (annual)
- ₹2,545 Cr
- Net profit (annual)
- ₹13.76 Cr
- P/E (TTM)
- 751.6×Sector 54.5×
- Promoter holding
- 64.21%+0.00% QoQ
- FII holding
- 2.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Healthcare Global Enterprises Ltd
All →Healthcare Global Enterprises Earnings Call Transcript: Key Takeaways
Q2 revenue ₹732 Cr, +16% YoY; H1 ₹1,410 Cr, +15%. EBITDA margin 19.7% despite ~₹6 Cr wage-revision hit. Trade-margin cap guided at mid-to-high single-digit annualised impact, with few specifics.
Healthcare Global Enterprises Results Update
HCG reported Q2 FY27 revenue of INR 7,318 Mn, up 16% YoY, with adjusted EBITDA up 17%. Results cover the quarter and half-year ended September 30, 2026.
Healthcare Global Enterprises Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 7,318 Mn (+16% YoY) and Adjusted EBITDA INR 1,425 Mn (+17%, 19.7% margin). Reported PAT INR 92.5 Mn. Plan to add 1,000 beds by FY30.
Healthcare Global Enterprises Employee Stock Options
HealthCare Global granted 70,000 employee stock options at a Rs 495 exercise price under its 2026 ESOS. Options vest within one to seven years.
- Execution
- Vesting 1 to 7 years from grant; exercisable for up to 10 years from grant
Healthcare Global Enterprises Q2 FY27 Results: Net Profit ₹9.2 Cr, Down 55.6% YoY
Healthcare Global Enterprises Ltd reported revenue from operations of ₹731.8 Cr (+13.1% YoY) and net profit of ₹9.2 Cr (-55.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹9.2 Cr · -55.6% YoY
Healthcare Global Enterprises Other Announcement
HealthCare Global Enterprises Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.